Radionetics Oncology is a clinical stage radiopharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/05/24 | $52,200,000 | Series A |
5AM Ventures Crinetics Pharmaceuticals DCVC Bio Frazier Life Sciences GordonMD Global Investments | undisclosed |
